Striving for a greater understanding to make a greater difference
Parkinson's disease non motor symptoms (NMS) are not well recognised in clinical practice. Part of the reason for this is the lack of any instrument that aims to assess the complex range of NMS of PD in an unified and integrated manner.
The PDNMG is a non profit academic organisation and acknowledges educational grants and funding from Boehringer Ingelheim, Britannia Pharmaceuticals, Lundbeck Ltd, Teva Pharmaceuticals, UCB Pharma Ltd, Abbvie, GE Healthcare, Medtronic, Mundipharma Research Ltd and Pfizer Ltd.
The website is hosted and managed on behalf of the PDNMG by Britannia Pharmaceuticals. Britannia does not seek to influence the content in any way.